Please wait while the formulary information is being retrieved.
PANRETIN (ALITRETINOIN)
- Kaposi's sarcoma skin lesions
0.1 % topical gel
- Apply to the affected area(s) by topical route 2 times per day
Kaposi's sarcoma skin lesions
- Apply to the affected area(s) by topical route 2 times per day
- Apply to the affected area(s) by topical route 3 times per day
- Apply to the affected area(s) by topical route 4 times per day
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Pregnancy
Contraindicated
- Mycosis fungoides
Severe
Moderate
- None
PANRETIN (ALITRETINOIN)
- Kaposi's sarcoma skin lesions
- Exfoliative dermatitis
- Paresthesia
- Skin fissure
- Skin irritation
- Skin rash
- Skin swelling
- Superficial skin ulcer
- Pruritus of skin
More Frequent
Severe
Less Severe
- None
- Skin photosensitivity
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Alitretinoin
- Severity Level:
1
- Additional Notes:
Contraindicated
Alitretinoin
Mfr recommends discontinuing breastfeeding prior to using drug.
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends discontinuing breastfeeding prior to using drug. |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Kaposi's sarcoma skin lesions | |
C46.0 | Kaposi's sarcoma of skin |
0-9 | A-Z |
---|---|
C46.0 | Kaposi's sarcoma of skin |
Formulary Reference Tool